Mast Therapeutics (MSTX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Mast Therapeutics Reports Second Quarter 2015 Financial Results
August 12, 2015 4:05 PM EDTSAN DIEGO, Aug. 12, 2015 /PRNewswire/ --Â Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today reported financial results for the quarter ended June 30, 2015.
"Our biggest priority in the second quarter of 2015 was continuing the enthusiasm and momentum for enrollment in EPIC, our Phase 3 trial of vepoloxamer, and we are pleased to... More
